Healthcare resource use by PSVT patients undergoing cardiac ablation
HEORStrategies’ Dr. Naomi Sacks is a co-author on a study of healthcare resource use and costs in cardiac arrhythmia patients with paroxysmal supraventricular… read more
Latest News
HEORStrategies’ Dr. Naomi Sacks is a Co-Author on a Study of Trends in Myasthenia Gravis Hospitalizations and Mortality
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study on myasthenia gravis (MG) just published in the journal Neurology. MG… read more
HEORStrategies’ Dr. Naomi Sacks is a co-author on a large-scale study of obesity and overweight in the United States
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study just published in the journal Obesity Science and Practice. Using national… read more
Announcing HEORStrategies, the newest division of ToxStrategies LLC!
HEORStrategies provides robust, strategic health economics and outcomes research (HEOR) consulting services to pharma, biotech, and medical device clients!
HEORStrategies’ Dr. Naomi Sacks presented on prevalence and treatment failure in UTI and acute cystitis at IDWeek 2023
HEORStrategies’ scientist Dr. Naomi Sacks, along with clinicians and industry leaders, presented study results of uncomplicated UTI (uUTI) in the US and acute… read more
Dr. Michael Kelsh joins EpidStrategies, a Division of ToxStrategies LLC
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
New Infant RSV Prevention to be Available this Fall
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more
ToxStrategies Acquires Modality Solutions
ToxStrategies LLC is excited to announce that Modality Solutions is joining forces with our firm, greatly expanding our ability to serve the evolving needs of… read more